Detailed Narrative
Q4 & FY26 Performance Overview
Fredun Pharmaceuticals delivered a strong financial performance for Q4 and full FY26. Total income for Q4 FY26 grew by 27.27% year-on-year to INR 213 crores, with EBITDA increasing by 67.05% to INR 29.13 crores, leading to a margin expansion of 326 basis points to 13.67%. Net profit for the quarter rose by 56.47% to INR 11.07 crores. For the full FY26, total income reached INR 639.12 crores, marking a 40.08% year-on-year growth, and EBITDA stood at INR 94.79 crores, up 72.05% with a margin of 14.83%.
New Product Launches: Hormonal & Anti-aging Lines
The company is launching two new product sets: a hormonal line and an anti-aging line. These products are targeted through the doctor channel, with Fredun aiming to be among the first in the country to offer certain hormonal products and specialized anti-aging solutions. The anti-aging segment, particularly NAD/NAD+, is seeing rapid growth, and Fredun holds exclusive import rights for its API, leveraging its dermaceutic and specialized product capabilities.
Mobility Division Growth Strategy
The Mobility division, encompassing brands like BraceOn, Digion, and NebOn, has shown phenomenal growth, achieving approximately INR 30 crores in FY26. Management projects this division to reach an INR 100 crores run rate within 2 to 2.5 years and an enterprise value of INR 250-300 crores within 5 to 7 years. The strategy leverages existing distribution channels used for pharma products, providing a competitive advantage over pure mobility players.
Pet Care Business Vision & Strategy
Fredun Pharmaceuticals has an ambitious long-term vision for its pet care business, aiming for no pet in India to be born or die without using a Freossi product or service by 2032-2033. The company is launching 42 variants of functional food biscuits, including novel Jain biscuits, and has developed a strong range of grooming products. The strategy focuses on educating first-line influencers like breeders and groomers, and the company's online platform, Wagr.in, is set for launch by early July, designed as a holistic pet care portal.
Raw Material Costs & Geopolitical Impact
Despite geopolitical issues leading to increased raw material costs, Fredun Pharmaceuticals successfully navigated the challenge. Management stated that maintaining 3-4 months of buffer stock and having orders in hand for 6-7 months (upwards of INR 320-330 crores) allowed them to absorb initial price shocks without significant impact on profitability. This proactive inventory management and forward ordering strategy even contributed to increased sales.
Manufacturing Capacity & In-house Production
The company emphasizes its strong in-house manufacturing capabilities, with over 80% of its products currently manufactured internally. Fredun is actively augmenting its capacities, planning to add 12 to 13 packing lines by the end of September and constructing a new wing within its plant. Management aims for Fredun to be among the top 3-4 manufacturing plants in terms of capacity at certain locations within the next 2.5 years, leveraging its three decades of experience and high CoPPs.
Working Capital Management & Cash Flow
Addressing investor concerns about working capital, management confirmed that cash flows have significantly improved, with the company now generating positive cash flows from operations. The debt-to-equity ratio stands at 0.8, and management asserted that working capital is not a current concern, highlighting that the improved numbers and strategic management of working capital were part of a planned decision to support rapid organic growth.